Showing 61,961 - 61,980 results of 62,523 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 5 ((step decrease) OR (we decrease)) ))', query time: 1.34s Refine Results
  1. 61961

    Image2.JPEG by Jennifer L. Reed (115264)

    Published 2018
    “…Weekly moderate-to-vigorous intensity PA (MVPA) changed over time (F = 4.022, df = 4.827, p = 0.002, η<sup>2</sup> = 0.055), and was greater during intervention week 2 when compared to intervention week 6 (p = 0.011). Daily steps changed over time (F = 7.668, df = 3.910, p < 0.001, η<sup>2</sup> = 0.100), and were greater during baseline and intervention weeks 1, 2, 3, and 5 when compared to intervention week 6 (p < 0.05). …”
  2. 61962

    Image3.JPEG by Jennifer L. Reed (115264)

    Published 2018
    “…Weekly moderate-to-vigorous intensity PA (MVPA) changed over time (F = 4.022, df = 4.827, p = 0.002, η<sup>2</sup> = 0.055), and was greater during intervention week 2 when compared to intervention week 6 (p = 0.011). Daily steps changed over time (F = 7.668, df = 3.910, p < 0.001, η<sup>2</sup> = 0.100), and were greater during baseline and intervention weeks 1, 2, 3, and 5 when compared to intervention week 6 (p < 0.05). …”
  3. 61963

    Image1.JPEG by Jennifer L. Reed (115264)

    Published 2018
    “…Weekly moderate-to-vigorous intensity PA (MVPA) changed over time (F = 4.022, df = 4.827, p = 0.002, η<sup>2</sup> = 0.055), and was greater during intervention week 2 when compared to intervention week 6 (p = 0.011). Daily steps changed over time (F = 7.668, df = 3.910, p < 0.001, η<sup>2</sup> = 0.100), and were greater during baseline and intervention weeks 1, 2, 3, and 5 when compared to intervention week 6 (p < 0.05). …”
  4. 61964

    Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021 by Comfort, Haley

    Published 2024
    “…The estimated number of stillbirths occurring at 20 weeks' gestation or longer decreased from 5·08 million (95% UI 4·07–6·35) in 1990 to 3·04 million (2·61–3·62) in 2021, corresponding to a 39·8% (31·8–48·0) reduction, which lagged behind a global improvement in neonatal deaths of 45·6% (36·3–53·1) for the same period (down from 4·03 million [3·86–4·22] neonatal deaths in 1990). …”
    Get full text
    Get full text
    Get full text
    article
  5. 61965
  6. 61966

    DataSheet1_Peripheral and intestinal mucosal-associated invariant T cells in premature infants with necrotizing enterocolitis.PDF by Jiayi Tian (6843836)

    Published 2022
    “…The frequency of MAIT cells in the intestinal tissues of five NEC patients and five control subjects was also examined. …”
  7. 61967

    Presentation1_Peripheral and intestinal mucosal-associated invariant T cells in premature infants with necrotizing enterocolitis.pdf by Jiayi Tian (6843836)

    Published 2022
    “…The frequency of MAIT cells in the intestinal tissues of five NEC patients and five control subjects was also examined. …”
  8. 61968
  9. 61969
  10. 61970
  11. 61971
  12. 61972
  13. 61973

    Enhancing oil removal from water using ferric oxide nanoparticles doped carbon nanotubes adsorbents by Fard, Ahmad Kayvani

    Published 2016
    “…The high hydrophobicity of CNTs makes them good candidates to enhance the de-oiling process from wastewater. In this study, we have reported the synthesis and evaluation of novel iron-oxide/CNTs nanocomposites for oil-water separation. …”
    Get full text
    Get full text
  14. 61974
  15. 61975

    DataSheet_1_Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients.docx by Sara Caldrer (11780336)

    Published 2021
    “…Background<p>The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. …”
  16. 61976
  17. 61977

    KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker by Nina-Naomi Kreis (460814)

    Published 2024
    “…Indeed, an increasing number of publications indicate that KIF2C is aberrantly expressed in multiple cancer entities. Consequently, we have highlighted its involvement in at least five hallmarks of cancer, namely: genome instability, resisting cell death, activating invasion and metastasis, avoiding immune destruction and cellular senescence. …”
  18. 61978

    DataSheet_1_Pollen and spore records constrained by millennial prodelta evolution: a case study of the Huanghe (Yellow River) delta.docx by Weifen Hu (18271333)

    Published 2024
    “…However, uncertainties in these reconstructions arise from millennial-scale prodelta evolution, which dominates stratigraphic development and consequently influences sedimentary processes and/or pollen provenance. Here we explore the intricate relationship between pollen/spore records and prodelta stratigraphic evolution, using established seismic stratigraphy and ten sediment cores (five new, five from literature) within both the proximal and distal (mud belt) parts of the Huanghe (Yellow River) prodelta. …”
  19. 61979

    Natural Selection Mediated Association of the Duffy (<em>FY</em>) Gene Polymorphisms with <em>Plasmodium vivax</em> Malaria in India by Anita Chittoria (132811)

    Published 2012
    “…Furthermore, vivax malaria incidences over the past five years were significantly negatively and positively associated with the frequencies of the <em>FY*A</em> and <em>FY*B</em> alleles, respectively. …”
  20. 61980

    CRISPR/Cas9-mediated editing of barley lipoxygenase genes promotes grain fatty acid accumulation and storability by Zhanghui Zeng (3571331)

    Published 2025
    “…Although the genetic engineering of <i>LOXs</i> holds great potential for improving grain storage quality, this approach remains largely unexplored in barley. In this study, we identified five <i>LOX</i> genes in the barley genome: <i>HvLOXA</i>, <i>HvLOXB</i>, and <i>HvLOXC1–3</i>. …”